关注
George L Daikos
标题
引用次数
引用次数
年份
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population …
A Cassini, LD Högberg, D Plachouras, A Quattrocchi, A Hoxha, ...
The Lancet infectious diseases 19 (1), 56-66, 2019
29442019
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
LS Munoz-Price, L Poirel, RA Bonomo, MJ Schwaber, GL Daikos, ...
The Lancet infectious diseases 13 (9), 785-796, 2013
18852013
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions
LS Tzouvelekis, A Markogiannakis, M Psichogiou, PT Tassios, GL Daikos
Clinical microbiology reviews 25 (4), 682-707, 2012
14772012
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
BT Tsuji, JM Pogue, AP Zavascki, M Paul, GL Daikos, A Forrest, ...
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (1 …, 2019
7232019
Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems
GL Daikos, S Tsaousi, LS Tzouvelekis, I Anyfantis, M Psichogiou, ...
Antimicrobial agents and chemotherapy 58 (4), 2322-2328, 2014
7172014
Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
The Journal of infectious diseases 197 (8), 1133-1144, 2008
5792008
An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection
MA Fischl, RB Uttamchandani, GL Daikos, RB Poblete, JN Moreno, ...
Annals of internal medicine 117 (3), 177-183, 1992
5421992
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
M Paul, GL Daikos, E Durante-Mangoni, D Yahav, Y Carmeli, YD Benattar, ...
The lancet Infectious diseases 18 (4), 391-400, 2018
5292018
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective …
B Gutiérrez-Gutiérrez, E Salamanca, M de Cueto, PR Hsueh, P Viale, ...
The Lancet Infectious Diseases 17 (7), 726-734, 2017
4892017
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli …
M Paul, E Carrara, P Retamar, T Tängdén, R Bitterman, RA Bonomo, ...
Clinical Microbiology and Infection 28 (4), 521-547, 2022
4672022
Treating infections caused by carbapenemase-producing Enterobacteriaceae
LS Tzouvelekis, A Markogiannakis, E Piperaki, M Souli, GL Daikos
Clinical Microbiology and Infection 20 (9), 862-872, 2014
4082014
Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial
RG Wunderink, EJ Giamarellos-Bourboulis, G Rahav, AJ Mathers, ...
Infectious diseases and therapy 7 (4), 439-455, 2018
3892018
Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control
Y Carmeli, M Akova, G Cornaglia, GL Daikos, J Garau, S Harbarth, ...
Clinical Microbiology and Infection 16 (2), 102-111, 2010
3632010
Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli
MA Fischl, GL Daikos, RB Uttamchandani, RB Poblete, JN Moreno, ...
Annals of internal medicine 117 (3), 184-190, 1992
3511992
Carbapenemase-producing Klebsiella pneumoniae:(when) might we still consider treating with carbapenems?
GL Daikos, A Markogiannakis
Clinical Microbiology and Infection 17 (8), 1135-1141, 2011
3292011
Prospective Observational Study of the Impact of VIM-1 Metallo-β-Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream Infections
GL Daikos, P Petrikkos, M Psichogiou, C Kosmidis, E Vryonis, A Skoutelis, ...
Antimicrobial agents and chemotherapy 53 (5), 1868-1873, 2009
2872009
Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from …
AP Magiorakos, K Burns, J Rodríguez Baño, M Borg, G Daikos, U Dumpis, ...
Antimicrobial Resistance & Infection Control 6, 1-17, 2017
2842017
Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria
M Akova, GL Daikos, L Tzouvelekis, Y Carmeli
Clinical Microbiology and Infection 18 (5), 439-448, 2012
2782012
Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome
RB Uttamchandani, GL Daikos, RR Reyes, MA Fischl, GM Dickinson, ...
Clinical infectious diseases 18 (3), 348-353, 1994
2601994
Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV …
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
The Journal of infectious diseases 197 (8), 1145-1155, 2008
2572008
系统目前无法执行此操作,请稍后再试。
文章 1–20